Key Development A new report from UNAIDS warns that the global response to HIV is entering a critical phase after... Read more
Category: Uncategorized
POTENTIAL WIDESPREAD CYCLOSPORA CONTAMINATION IN CENTRAL MEXICO RAISES NEW QUESTIONS ABOUT GLOBAL FOOD SAFETY OVERSIGHT
Key Development A new assessment from former U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb suggests the ongoing cyclosporiasis... Read more
JOHNSON & JOHNSON’S US$5.5 BILLION TALC SETTLEMENT MARKS A PIVOTAL SHIFT IN PHARMACEUTICAL LITIGATION STRATEGY
Key Development Johnson & Johnson has announced a proposed US$5.5 billion settlement to resolve approximately 69,000 remaining lawsuits alleging that... Read more
ASTRAZENECA FACES A NEW TEST OF ITS GROWTH STRATEGY AS RARE DISEASE EXPANSION ENCOUNTERS A CLINICAL SETBACK
Key Development Not every late stage clinical failure changes the trajectory of a pharmaceutical company, but every unsuccessful trial provides... Read more
NATIONWIDE COSMETIC RECALL HIGHLIGHTS THE GROWING IMPORTANCE OF QUALITY ASSURANCE IN VIETNAM’S PERSONAL CARE MARKET
Key Development Vietnam's Drug Administration has ordered a nationwide recall of two cosmetic product batches including Oatrum body cleansing gel... Read more
GERMANY’S SICK LEAVE CRACKDOWN HIGHLIGHTS DEEPER CHALLENGES FOR HEALTHCARE AND WORKFORCE PRODUCTIVITY
Key Development Germany is considering stricter oversight of employee sick leave as rising absenteeism and labour costs fuel concerns among... Read more
ARGENX’S $2.2 BILLION FORTE ACQUISITION SIGNALS A NEW WAVE OF IMMUNOLOGY CONSOLIDATION
Key Development Argenx has agreed to acquire Forte Biosciences in a transaction valued at approximately $2.2 billion, representing one of... Read more
POSITIVE CHMP OPINION BRINGS A NEW CHOLESTEROL LOWERING THERAPY CLOSER TO THE EUROPEAN MARKET
Key Development The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing... Read more
FDA APPROVAL OF LYTENAVA RESHAPES THE COMPETITIVE LANDSCAPE IN WET AMD TREATMENT
Key Development The US Food and Drug Administration has approved Outlook Therapeutics' Lytenava for the treatment of wet age related... Read more









